Analisis Potensi Dampak Perjanjian TRIPs pada Ketersediaan Obat dan Vaksin Covid-19

https://doi.org/10.22146/farmaseutik.v19i1.71576

Mario Franky Joris(1*), Kadek Maylena Putri Yuliawan(2), Dwi Endarti(3)

(1) Gadjah Mada University
(2) Gadjah Mada University
(3) Gadjah Mada University
(*) Corresponding Author

Abstract


ABSTRAK


Adanya perjanjian TRIPs membuat aksesibilitas obat dan pelayanan kesehatan menjadi terhambat karena dibatasi oleh adanya paten, terutama pada masa pandemi Covid-19. Studi ini bertujuan untuk menganalisis dampak dari implementasi TRIPs terhadap ketersediaan obat dan vaksin Covid-19 pada beberapa negara selama masa pandemi. Studi ini dilakukan dengan menggunakan metode studi pustaka, dimana dilakukan pencarian literatur menggunakan berbagai macam database dan kata kunci. Hasilnya, dalam pelaksanaan TRIPs, TRIPs menghalangi ketersediaan obat-obatan esensial, terutama di negara berkembang. Maka dari itu, muncul fleksibilitas TRIPs yang dianggap dapat menjadi opsi dan solusi dalam mengatasi aksesibilitas pelayanan kesehatan, terutama obat dan vaksin Covid-19 selama masa pandemi. Dengan adanya fleksibilitas TRIPs, banyak negara dan juga perusahaan farmasi yang memanfaatkan fleksibilitas ini sehingga menjamin ketersediaan obat dan vaksin esensial untuk penanganan pandemi Covid-19. 


Kata Kunci: Covid-19; fleksibilitas TRIPs; ketersediaan obat; TRIPs; vaksin Covid-19. 



ABSTRACT

The existence of the TRIPs agreement has hampered the accessibility of drugs and health services because they are limited by the existence of patents, especially during the Covid-19 pandemic. This study aims to analyze the impact of implementing TRIPs on the availability of Covid-19 drugs and vaccines in several countries during the pandemic. This study was conducted using the literature study method, where a literature search was carried out using various databases and keywords. As a result, in the implementation of TRIPs, TRIPs hinder the availability of essential medicines, especially in developing countries. Therefore, the TRIPs flexibility has emerged which is considered to be an option and solution in overcoming the accessibility of health services, especially drugs and Covid-19 vaccines during the pandemic. With the flexibility of TRIPs, many countries as well as pharmaceutical companies are taking advantage of this flexibility to ensure the availability of essential drugs and vaccines for handling the Covid-19 pandemic.


Keyword: Covid-19; TRIPs flexibility; drug availability; TRIPs; Covid-19 vaccine.



Keywords


Covid-19; fleksibilitas TRIPs; ketersediaan obat; TRIPs; vaksin Covid-19.

Full Text:

PDF


References

DAFTAR PUSTAKA

Annisa, 2021. 'Presiden Jokowi Resmi Terbitkan Perpres Paten Remdesivir & Favipiravir', Law-Justice. Dikutip dari https://www.law-justice.co/artikel/120472/presiden-jokowi-resmi-terbitkan-perpres-paten-remdesivir--favipiravir/ pada 29 November 2021.

Anonim, 2015, Using TRIPS flexibilities to improve access to HIV treatment, UNAIDS, WHO, and UNDP Policy Briefs.

Anonim, 2016, Undang-Undang No 13 Tahun 2010 tentang Paten, Departemen Kesehatan Republik Indonesia.

Anonim, 2021, Which Vaccines Has Been Registered in Each Country?, Retrieved From : https://ourworldindata.org/covid-vaccinations#licence pada 28 November 2021.

Bianco F L., 2021, Comparative Patent Compulsory Licensing Under COVID-19 Is It Influencing Big Pharma?, University of Enna Kore.

Cerilles, J.M.C. dan Fernan, H.G.O.M., 2021. Analysing the interplay between the right to health and pharmaceutical patent rights in the introduction of a COVID-19 vaccine into the Philippines. International Journal of Human Rights in Healthcare, 14: 240–254.

Chattu, V.K., Singh, B., Kaur, J., dan Jakovljevic, M., 2021. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India’s Role at the WTO Platform. BioMed Research International, 2021: 6658070.

Chaudhary, T. dan Chaudhary, A., 2021. TRIPS waiver of COVID-19 vaccines: Impact on pharmaceutical industry and what it means to developing countries. The Journal of World Intellectual Property, 24: 447–454.

Correa, C.M., Hilty, R.M., dan Global Forum on Innovation, I.P. and A. to M., 2021. Access to Medicines and Vaccines: Implementing Flexibilities under Intellectual Property Law.

Cornet et al., 2021, Hydroxychloroquine Availability During COVID-19 Crisis and Its Effect on Patient Anxiety, Lupus Science & Medicines.

De Carvalho, Nuno Pires. The TRIPS regime of patent rights. Kluwer law international, 2010.

Imran, Mohd., Alshrari, A.S., Asdaq, S.M.B., dan Abida, 2021. Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review. Journal of Infection and Public Health, 14: 1075–1086.

Labonte, R. dan Johri M., 2020, Covid-19 Drug and Vaccine Patents are Putting Profit before People. The Conversation. Diakses dari http://globalhealthequity.ca/wp-content/uploads/2020/11/COVID-19-drug-and-vaccine-patents-are-putting-profit-before-people.pdf pada 16 November 2021.

McMahon A., 2020, Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governanceJournal of Medical Ethics 2021;47:142-148.

Medicines Patent Pool, 2021a. COVID-19. MPP’s Contribution to The Global Response to Covid-19. Dikutip dari https://medicinespatentpool.org/covid-19 pada 24 November 2021.

Medicines Patent Pool, 2021b. MPP & MSD announce new licence for investigational COVID-19 treatment. MPP. Dikutip dari https://medicinespatentpool.org/news-publications-post/mpp-msd-new-licence-announcement-molnupiravir pada 24 November 2021.

Medicines Patent Pool, 2021. Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries. MPP. Dikutip dari https://medicinespatentpool.org/news-publications-post/pfizer-and-the-medicines-patent-pool-mpp-sign-licensing-agreement-for-covid-19-oral-antiviral-treatment-candidate-to-expand-access-in-low-and-middle-income-countries pada 24 November 2021.

Moerman, L. dan Van Der Laan, S., 2006. TRIPS and the pharmaceutical industry: Prescription for profit? Critical Perspectives on Accounting, 17: 1089–1106.

Motari, M., Nikiema, J.-B., Kasilo, O.M.J., Kniazkov, S., Loua, A., Sougou, A., dkk., 2021. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement. BMC Public Health, 21: 490.

Muis, Lidya Shery. "Hak Atas Aksesibilitas Obat Paten Bagi Masyarakat." Widya Pranata Hukum: Jurnal Kajian dan Penelitian Hukum 1.1 (2019): 36-64.

Serohina, N., Pikhurets, O., Iasechko, S., Yevlakhova, E., dan Lytvyn, S., 2021. Application of Compulsory Licensing in the Context of the Covid-19 Coronavirus Pandemic. Systematic Reviews in Pharmacy, 12: 9.

Sinaga V S., 2015, Ancaman Paten Terhadap Akses Publik dan TRIPs Safeguard, Retrieved From: https://m.atmajaya.ac.id/web/KontenUnit.aspx?gid=artikel-hki&ou=hki&cid=ancaman-paten-terhadap-kesehatan-publik-dan-safeguards-trips pada 28 November 2021.

Subhan, J., 2006. Scrutinized: The TRIPS Agreement and Public Health. McGill Journal of Medicine : MJM, 9: 152–159.

Taubman, A., Wager, H., dan Watal, J. (Editor), 2020. A Handbook on the WTO TRIPS Agreement, 2nd ed. Cambridge University Press.

Munoz Tellez, V., 2020. The COVID-19 Pandemic: R&D and Intellectual Property Management for Access to Diagnostics, Medicines and Vaccines. SSRN Electronic Journal.

Wong, H., 2020. The case for compulsory licensing during COVID-19. Journal of Global Health, 10: 010358.

World Health Organization, 2021. Vaccines/COVID-19 vaccine EUL issued, WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control. Dikutip dari https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued pada 23 November 2021.

World Trade Organization, n.d. 'WTO | Doha Declaration explained. Dikutip dari https://www.wto.org/english/tratop_e/dda_e/dohaexplained_e.htm pada 16 November 2021.



DOI: https://doi.org/10.22146/farmaseutik.v19i1.71576

Article Metrics

Abstract views : 802 | views : 1387

Refbacks



Majalah Farmaseutik Indexed by:

   
 
Creative Commons Licence
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.